HCV, HIV AND HBV rapid test diagnosis in non-clinical outreach settings can be as accurate as conventional laboratory tests.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 05 2023
Historique:
received: 08 04 2022
accepted: 20 04 2023
medline: 11 5 2023
pubmed: 10 5 2023
entrez: 10 5 2023
Statut: epublish

Résumé

Point of care rapid diagnostic tests (POC-RDT) for Hepatitis C virus (HCV), Human Immunodeficiency virus (HIV) and Hepatitis B virus (HBV), are ideal for screening in non-clinical outreach settings as they can provide immediate results and facilitate diagnosis, allowing high risk population screening. The aim of this study was to compare POC-RDT with laboratory conventional tests. A total of 301 vulnerable evaluable subjects (drug users, migrants and homeless population) were recruited at a mobile screening unit in outreach settings in Madrid. Fingerprick whole blood capillary samples were tested using the SD BIOLINE HCV POC-RDT, Determine HIV Early Detect and Determine HBsAg 2, and the results were assessed against the LIAISON XL HCV, HIV and Murex-HBsAg-Quant, reference assays, respectively. The feasibility and user satisfaction of the POC-RDT were evaluated through a questionnaire. The resolved sensitivity and resolved specificity and their 95% confidence intervals (95% CI) were as follows, respectively: SD-BIOLINE-HCV: 98.8% (95% CI 93.4, 100.0) and 100.0% (95% CI 98.3, 100.0); Determine HIV Early Detect: 100% (95% CI 85.2, 100.0) and 100% (95% CI 98.7, 100); and Determine HBsAg 2: 66.7% (95% CI 9.4, 99.2) and 100.0% (95% CI 98.7, 100.0). As expected, the number of subjects with a confirmed positive result for HBsAg was very low (n = 4). Therefore, the analytical sensitivity has been evaluated in addition: The Determine HBsAg 2 test demonstrated 100% sensitivity for standard concentrations ≥ 0.125 IU/mL. The subject questionnaire yielded positive feedback for most subjects. The POC-RDT fingerprick blood collection method was well received, and the tests demonstrated a comparable clinical performance with conventional tests in outreach settings and vulnerable high-risk populations.

Identifiants

pubmed: 37160925
doi: 10.1038/s41598-023-33925-2
pii: 10.1038/s41598-023-33925-2
pmc: PMC10170094
doi:

Substances chimiques

Hepatitis B Surface Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7554

Informations de copyright

© 2023. The Author(s).

Références

J Int AIDS Soc. 2017 Jul 28;20(1):22146
pubmed: 28782335
J Infect Dis. 2019 Jun 5;220(1):78-90
pubmed: 30726973
Gastroenterol Hepatol. 2016 Dec;39(10):656-662
pubmed: 27417563
Eur J Gastroenterol Hepatol. 2017 Jun;29(6):629-633
pubmed: 28230562
J Hepatol. 2021 Feb;74(2):474-475
pubmed: 33229012
Clin Infect Dis. 2014 Sep 15;59(6):875-82
pubmed: 24867787
Enferm Infecc Microbiol Clin (Engl Ed). 2020 Feb;38(2):94-95
pubmed: 31248725
BMC Infect Dis. 2013 Apr 18;13:181
pubmed: 23597411
HIV Med. 2022 Mar;23(3):237-248
pubmed: 34693615
Malays J Med Sci. 2019 May;26(3):37-48
pubmed: 31303849
Open Forum Infect Dis. 2022 Apr 14;9(6):ofac181
pubmed: 35774932
BMC Infect Dis. 2020 Nov 16;20(1):851
pubmed: 33198672
J Med Virol. 2020 Apr 9;:
pubmed: 32270883
PLoS One. 2016 Mar 31;11(3):e0151946
pubmed: 27031352
PLoS One. 2022 May 31;17(5):e0269250
pubmed: 35639675
Int J STD AIDS. 2009 Feb;20(2):77-83
pubmed: 19182051
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):695
pubmed: 29143615

Auteurs

Milagros Muñoz-Chimeno (M)

Hepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.

Jorge Valencia (J)

Infanta Leonor Hospital, Madrid, Spain.

Alvaro Rodriguez-Recio (A)

Hepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.

Guillermo Cuevas (G)

Infanta Leonor Hospital, Madrid, Spain.

Alejandra Garcia-Lugo (A)

Hepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.

Samuel Manzano (S)

Infanta Leonor Hospital, Madrid, Spain.

Vanessa Rodriguez-Paredes (V)

Hepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.

Beatriz Fernandez (B)

Infanta Leonor Hospital, Madrid, Spain.

Lucía Morago (L)

Hepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.

Concepción Casado (C)

Molecular Virology Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.

Ana Avellón (A)

Hepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain. aavellon@isciii.es.
CIBERESP Epidemiology and Public Health, Madrid, Spain. aavellon@isciii.es.

Pablo Ryan (P)

Infanta Leonor Hospital, Madrid, Spain. pablo.ryan@salud.madrid.org.
CIBER Infectious Diseases (CB 21/13/00044), Madrid, Spain. pablo.ryan@salud.madrid.org.
Complutense University of Madrid, Madrid, Spain. pablo.ryan@salud.madrid.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH